Study guide
17.1 Quality Planning and Risk Management
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
17.1 Quality Planning and Risk Management
Key Takeaways Explain This Topic AI
Quality management identifies important data and processes before failures occur.
Risk assessment considers likelihood, impact and detectability.
Controls should be reviewed as trial experience and information change.
Last updated: October 2026
Quality Planning and Risk Management
Note
Under ICH E6(R3), the sponsor is required to implement a system to manage quality throughout all stages of the trial process. Quality management includes the design of efficient clinical trial protocols and tools and procedures for data collection and processing, as well as the collection of information that is essential to decision making. The methods used to assure and control the quality of the trial should be proportionate to the inherent risks of the trial and the importance of the information collected.
Modern clinical trial execution has departed decisively from the historical paradigm of reactive quality control. Historically, sponsors and Clinical Research Associates (CRAs) relied heavily on end-stage inspection—attempting to "inspect quality into" a clinical study by checking completed case report forms against hospital records. The current ICH framework supports the continuing transition toward prospective Risk-Based Quality Management (RBQM) and formal Quality Management Systems (QMS) .
For the professional CRA, quality management is not an administrative burden relegated to quality assurance auditors. It is an active operational discipline requiring the monitor to identify systemic vulnerabilities, facilitate rigorous Root Cause Analysis (RCA) when non-compliance emerges, and verify that investigative sites implement enforceable Corrective and Preventive Action (CAPA) plans targeting causes and supported by appropriate effectiveness verification.
The Quality Management System (QMS) Framework (ICH E6(R3))
E6(R3) and E8(R1) support a planned, iterative approach rooted in Quality by Design (QbD) . The core tenet of QbD is that quality cannot be tested or inspected into a clinical trial after data collection has concluded; it must be engineered prospectively into the protocol architecture, operational tools, and clinical workflows.
A practical quality-management cycle
Critical Process and Data Identification: Before study initiation, the sponsor must identify those clinical processes and data points that are essential to ensuring human subject protection and the reliability of study results. These are termed Critical-to-Quality (CtQ) factors (e.g., informed consent execution, primary efficacy endpoints, investigational product dosing accuracy, and serious adverse event reporting).
Risk Identification: The sponsor identifies risks to critical trial processes and data across protocol design, facility capabilities, clinical technologies, and participant vulnerabilities. Risk questions address: What could go wrong? What error would compromise patient safety or invalidate study results?
Risk Evaluation: Identified risks are evaluated by estimating the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on participant safety and data integrity.
Risk Control: The sponsor decides which risks are acceptable and which require proactive mitigation. Mitigation measures may include protocol design simplification, targeted CRA monitoring, automated system validation checks, or establishing predefined Quality Tolerance Limits (QTLs) .
Risk Communication: The sponsor actively communicates quality management strategies, identified risk thresholds, and monitoring priorities to all participating investigative site personnel, CRAs, vendors, and data managers.
Risk Review: Quality management is dynamic. The sponsor and monitors periodically re-evaluate risk controls throughout trial conduct to determine whether existing mitigations remain effective, whether operational assumptions were accurate, and whether newly emerging risks require protocol amendments or monitoring adjustments.
Risk Reporting: In accordance with ICH E6(R3), the sponsor must describe the quality management approach implemented in the trial and summarize important deviations from predefined quality tolerance limits and remedial actions taken within the final Clinical Study Report (CSR) .
Important
Quality by Design (QbD) dictates that unnecessary protocol complexity is the a potential driver of clinical trial deviations. Eliminating redundant assessments, streamlining patient visit schedules, and establishing clear operational endpoints prevent non-compliance far more effectively than intensifying on-site monitoring inspections after errors have occurred.
Root Cause Analysis (RCA) Methodologies in Clinical Research
When a protocol deviation, regulatory audit finding, or safety reporting breakdown occurs at an investigative site, the initial observation is almost never the true cause. It is merely a visible symptom of a deeper systemic flaw. If an investigative team treats only the symptom, the underlying failure mode remains active, allowing recurrence.
Root Cause Analysis (RCA) is a structured, problem-solving methodology directed at identifying the fundamental, systemic weakness that allowed a failure to occur. On the CCRA examination, candidates must recognize and apply three core RCA techniques:
The 5 Whys Technique
Originally developed in industrial manufacturing, the 5 Whys is an iterative interrogative technique used to explore the cause-and-effect relationships underlying a specific problem. By repeatedly asking "Why?" (typically five times), the investigator strips away superficial operational layers to expose the systemic failure.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .